HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Biocon’s arm secures exclusive global rights for Hulio
Dec-23-2025

Biocon’s subsidiary and a fully integrated global biosimilars company -- Biocon Biologics has secured full and exclusive global rights for Hulio (biosimilar Adalimumab) from Fujifilm Kyowa Kirin Biologics Co. (FKB). Under this new agreement, Biocon Biologics will assume end-to-end responsibility for manufacturing and commercialization along with rights for any additional development activities.

The new agreement supersedes the existing collaboration agreement between Biocon Biologics and FKB for biosimilar Adalimumab, under which Biocon Biologics only had commercialization rights. Under the terms of this agreement, FKB will participate in the development of the product and will offset certain development costs incurred by Biocon Biologics. In turn, Biocon Biologics will pay a technology license fee and royalties on sales to FKB for a specified tenure.

Biocon Biologics initially acquired the commercial rights to biosimilar Adalimumab in 2022 through its acquisition of Viatris’ global biosimilars business. Viatris had previously in-licensed the product from FKB. Under the earlier arrangement, FKB manufactures and supplies the product to Biocon Biologics, which holds global commercial rights for HULIO. Adalimumab is one of the three immunology biosimilars in Biocon Biologics’ overall portfolio, which underscores the company’s strategic focus on expanding access to biologics for immune-mediated diseases worldwide.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

  RELATED NEWS >>